Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
A Comprehensive Review of Nabumetone's R&D Innovations and Drug Target Mechanism
30 September 2023
This article summarized the latest R&D progress of Nabumetone, the Mechanism of Action for Nabumetone, and the drug target R&D trends for Nabumetone.
Valuable Targets
6 min read
Advances in Clinical Research on PARP1 inhibitors
30 September 2023
PARP1 is the most prominent member of the PARP family, accounting for 80%-90% of the enzyme activity, and is a key player in DNA damage repair.
Drug Insights
4 min read
Pharmaceutical Insights: Thiocolchicoside's R&D Progress and its Mechanism of Action on Drug Target
30 September 2023
This article summarized the latest R&D progress of Thiocolchicoside, the Mechanism of Action for Thiocolchicoside, and the drug target R&D trends for Thiocolchicoside.
Latest Hotspot
3 min read
Krystal Biotech reports FDA approval of the investigational new drug application for KB408 to treat Type 1 Alpha-1 Antitrypsin Deficiency
30 September 2023
Krystal Biotech publicized that the U.S. FDA has given the green light for the Investigational New Drug application for KB408 to manage alpha-1 antitrypsin deficiency.
Drug Insights
4 min read
Exploring Tianeptine Sodium's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
30 September 2023
This article summarized the latest R&D progress of Tianeptine Sodium, the Mechanism of Action for Tianeptine Sodium, and the drug target R&D trends for Tianeptine Sodium.
Valuable Targets
7 min read
Analysis on the Clinical Research Progress of PDL1 inhibitors
30 September 2023
Programmed death-ligand 1 (PD-L1) is a protein found on the surface of certain cells in the human body, including immune cells and some cancer cells.
Drug Insights
4 min read
Decoding Tibolone: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
30 September 2023
This article summarized the latest R&D progress of Tibolone, the Mechanism of Action for Tibolone, and the drug target R&D trends for Tibolone.
Latest Hotspot
3 min read
The European Commission has approved Jazz Pharmaceuticals' Enrylaze® for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma treatment
30 September 2023
Jazz Pharmaceuticals plc has proclaimed that the EC has approved the commercialization of Enrylaze®(JZP458; a derivative of Erwinia asparaginase or crisantaspase).
Drug Insights
4 min read
Deep Scientific Insights on Tofacitinib Citrate's R&D Progress, Mechanism of Action, and Drug Target
30 September 2023
This article summarized the latest R&D progress of Tofacitinib Citrate, the Mechanism of Action for Tofacitinib Citrate, and the drug target R&D trends for Tofacitinib Citrate.
Valuable Targets
7 min read
Cardiovascular Disease Treatment Drug - PDE3 Inhibitors
30 September 2023
PDE3 has the ability to hydrolyze both cAMP and cGMP, but its ability to hydrolyze cAMP is about ten times that of cGMP.
Drug Insights
4 min read
An In-depth Analysis of Tofisopam's R&D Progress and Mechanism of Action on Drug Target
30 September 2023
This article summarized the latest R&D progress of Tofisopam, the Mechanism of Action for Tofisopam, and the drug target R&D trends for Tofisopam.
Latest Hotspot
3 min read
Leucid Bio receives MHRA approval to clinically test LEU011, a Lateral NKG2D CAR-T Cell treatment
30 September 2023
Leucid Bio announced today its UK MHRA-approved CTA to commence Phase 1/2 AERIAL clinical trials of its drug, LEU011, for treating adult patients with relapsed or resistant solid tumours.